MCID: LYM019
MIFTS: 46

Lymphosarcoma

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Lymphosarcoma

MalaCards integrated aliases for Lymphosarcoma:

Name: Lymphosarcoma 52 54
Lymphoma, Diffuse 71
Lymphoma 71

Classifications:



External Ids:

UMLS 71 C0024299 C3714542

Summaries for Lymphosarcoma

MalaCards based summary : Lymphosarcoma, also known as lymphoma, diffuse, is related to reticulum cell sarcoma and follicular lymphoma. An important gene associated with Lymphosarcoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and Chromatin Regulation / Acetylation. The drugs Fosaprepitant and Ferrous succinate have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and lung, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 T-lymphoblastic leukemia/lymphoma (WHO 2008), previously labeled precursor T-lymphoblastic... more...

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 336)
# Related Disease Score Top Affiliating Genes
1 reticulum cell sarcoma 30.8 TNFRSF8 PTPRC
2 follicular lymphoma 29.7 IGH BCL6 BCL2
3 lymphoma, non-hodgkin, familial 29.7 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
4 lymphoblastic lymphoma 29.4 TNFRSF8 PTPRC BCL6
5 reticulosarcoma 29.1 TNFRSF8 PTPRC IGH BCL6 BCL2
6 immune deficiency disease 29.0 TNFRSF8 PTPRC ERVW-1 BCL6
7 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.0 TNFRSF8 PTPRC BCL6
8 leukemia, chronic myeloid 28.9 PTPRC G6PD DNMT1 BCL2
9 mantle cell lymphoma 28.8 PTPRC IGH BCL6 BCL2
10 leukemia, acute lymphoblastic 28.8 PTPRC NR3C1 IGH CD22 BCL6 BCL2
11 peripheral t-cell lymphoma 28.7 TNFRSF8 PTPRC DNMT3A BCL6
12 burkitt lymphoma 28.4 TNFRSF8 DNMT1 CD22 BCL6 BCL2
13 lymphoma, hodgkin, classic 28.4 TNFRSF8 PTPRC BCL6 BCL2
14 t-cell lymphoblastic leukemia/lymphoma 28.2 TNFRSF8 PTPRC NR3C1 ERVW-1 BCL2
15 leukemia, chronic lymphocytic 28.1 TNFRSF8 PTPRC IGH DNMT3A CD22 BCL6
16 leukemia, acute myeloid 28.0 TNFRSF8 PTPRC DNMT3A DNMT1 CD22 BCL6
17 myeloma, multiple 27.9 TNFRSF8 PTPRC DNMT1 CD22 BCL6 BCL2
18 b-cell lymphoma 27.9 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
19 leukemia 10.7
20 lymphoma 10.5
21 sarcoma 10.4
22 spindle cell sarcoma 10.4
23 acute leukemia 10.4
24 trimethoprim allergy 10.3 GSR G6PD
25 meningococcal infection 10.3 GSR G6PD
26 myeloid leukemia 10.3
27 eye lymphoma 10.2 CD22 BCL6
28 diarrhea 10.2
29 parotitis 10.2 H6PD G6PD
30 ataxia and polyneuropathy, adult-onset 10.2
31 neutropenia 10.2
32 hemolytic anemia 10.2
33 peritonitis 10.2
34 epiglottis neoplasm 10.2 PTPRC BCL6
35 heart lymphoma 10.2 PTPRC BCL6
36 posttransplant acute limbic encephalitis 10.2
37 plasmablastic lymphoma 10.1 PTPRC BCL6
38 intussusception 10.1
39 mycosis fungoides 10.1
40 hypereosinophilic syndrome 10.1
41 hypoglycemia 10.1
42 splenomegaly 10.1
43 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
44 yemenite deaf-blind hypopigmentation syndrome 10.1
45 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
46 deficiency anemia 10.1
47 uveitis 10.1
48 thrombocytopenia 10.1
49 fibrosarcoma 10.1
50 lymphopenia 10.1

Graphical network of the top 20 diseases related to Lymphosarcoma:



Diseases related to Lymphosarcoma

Symptoms & Phenotypes for Lymphosarcoma

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 CD22 CTSL DNMT3A NR3C1 PTPRC

MGI Mouse Phenotypes related to Lymphosarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 BCL2 BCL6 DNMT3A G6PD GSR NR3C1
2 cellular MP:0005384 9.91 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
3 endocrine/exocrine gland MP:0005379 9.76 BCL2 BCL6 DNMT3A H6PD NR3C1 PTPRC
4 hematopoietic system MP:0005397 9.65 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
5 immune system MP:0005387 9.28 BCL2 BCL6 CD22 DNMT1 DNMT3A NR3C1

Drugs & Therapeutics for Lymphosarcoma

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 846)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fosaprepitant Approved Phase 4 172673-20-0 219090
2
Ferrous succinate Approved Phase 4 10030-90-7
3
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
4
Tropisetron Approved, Investigational Phase 4 89565-68-4, 105826-92-4 5595
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
7
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Teniposide Approved Phase 4 29767-20-2 34698
11
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
12
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
13
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
14
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
15
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
16
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Nitric Oxide Approved Phase 4 10102-43-9 145068
19
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
20
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
21
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
22
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
23
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
24
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
25
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
29
Lithium carbonate Approved Phase 4 554-13-2
30
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
31
Prilocaine Approved Phase 4 721-50-6 4906
32
Epirubicin Approved Phase 4 56420-45-2 41867
33
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
34
Ofloxacin Approved Phase 4 82419-36-1 4583
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
36
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
37
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
38
Glucagon Approved Phase 4 16941-32-5
39
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
40
Liraglutide Approved Phase 4 204656-20-2 44147092
41
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
42
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
43
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
44
Ribavirin Approved Phase 4 36791-04-5 37542
45
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
46
Zidovudine Approved Phase 4 30516-87-1 35370
47
Methoxsalen Approved Phase 4 298-81-7 4114
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
50
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221

Interventional clinical trials:

(show top 50) (show all 7395)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
3 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
4 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
5 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
7 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
8 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
9 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
10 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
11 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
12 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
13 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
14 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
15 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
16 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
17 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
18 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
19 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
20 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
21 A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
22 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
23 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
24 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
25 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
26 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
27 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
28 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Unknown status NCT02006225 Phase 4 Plerixafor
29 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
30 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
31 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
32 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
33 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
34 Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. Unknown status NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
35 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
36 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
37 The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
38 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
39 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
40 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
41 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
42 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
43 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
44 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
45 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
46 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
47 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
48 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
49 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
50 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Lymphosarcoma

Anatomical Context for Lymphosarcoma

MalaCards organs/tissues related to Lymphosarcoma:

40
B Cells, T Cells, Lung, Bone, Bone Marrow, Myeloid, Breast

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

(show top 50) (show all 4218)
# Title Authors PMID Year
1
Suppression of metallothionein-I/II expression and its probable molecular mechanisms. 61 54
12426140 2002
2
[Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas]. 61 54
11494447 2001
3
Targeting Circulating SINEs and LINEs with DNase I Provides Metastases Inhibition in Experimental Tumor Models. 61
32146418 2020
4
[Application of Antinuclear Antibody and Antinuclear Antibody Spectrum in Lymphoma Treatment]. 61
32552948 2020
5
Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. 61
32153241 2020
6
Update on the subcutaneous administration of rituximab in Canadian cancer centres. 61
32489254 2020
7
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. 61
32030731 2020
8
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. 61
32135128 2020
9
To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma). 61
32073552 2020
10
An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. 61
32228625 2020
11
Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue. 61
32167380 2020
12
PTEN Loss and Cyclin A2 Upregulation Define a PI3K/AKT Pathway Activation in Helicobacter pylori-induced MALT and DLBCL Gastric Lymphoma With Features of MALT. 61
32134755 2020
13
Rare case of Richter's syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) - Case report and literature. 61
32208597 2020
14
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma. 61
32014922 2020
15
Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. 61
32457824 2020
16
Foliate Lymphoid Aggregates as Novel Forms of Serous Lymphocyte Entry Sites of Peritoneal B Cells and High-Grade B Cell Lymphomas. 61
31767783 2020
17
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. 61
31648953 2019
18
Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma. 61
31840115 2019
19
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. 61
31789821 2019
20
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis. 61
31759344 2019
21
Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives. 61
30993718 2019
22
Detection and Identification of Enzootic Bovine Leukosis (EBL) in Calves in Iran. 61
31592598 2019
23
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 61
30045683 2019
24
The Unsolved Puzzle of c-Rel in B Cell Lymphoma. 61
31277480 2019
25
Prevalence and clinical significance of koala retrovirus in two South Australian koala (Phascolarctos cinereus) populations. 61
31162024 2019
26
Surveillance scanning in lymphoma. 61
31437139 2019
27
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. 61
30795996 2019
28
Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. 61
30999803 2019
29
Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation. 61
30909988 2019
30
Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation? 61
30411396 2019
31
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). 61
29419530 2019
32
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. 61
30642819 2019
33
Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. 61
29795433 2019
34
Isolation, Purification, Characterisation and Application of L-ASNase: A Review. 61
30318009 2019
35
Massive bone marrow necrosis revealing an HIV-related primary bone marrow lymphoma: a diagnostic challenge. 61
30293217 2019
36
Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness. 61
29979613 2019
37
Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas. 61
31282408 2019
38
An unusual cause of colic stenosis in a renal transplant recipient: primary colonic diffuse large B-cell lymphoma. 61
30737361 2019
39
LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. 61
31552193 2019
40
Characterisation of infection associated microRNA and protein cargo in extracellular vesicles of Theileria annulata infected leukocytes. 61
30370674 2019
41
Long-term cadmium exposure enhances metallothionein-1 induction after subsequent exposure to high concentrations of cadmium in P1798 mouse lymphosarcoma cells. 61
30944283 2019
42
Neurolymphomatosis caused by T-cell lymphosarcoma in a cat: imaging description and treatment review. 61
30828460 2019
43
Lymphocyte proliferation and apoptosis of lymphocyte subpopulations in bovine leukemia virus-infected dairy cows with high and low proviral load. 61
30502911 2018
44
Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. 61
30087459 2018
45
Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases. 61
30111570 2018
46
Unusual behavior of diffuse large B-cell lymphoma as cardiac invasion with rapid spontaneous regression after fine needle aspiration cytology. 61
30476383 2018
47
Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma 61
30398157 2018
48
A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography. 61
30155702 2018
49
A Primary Retroperitoneal Diffuse Large B-Cell Lymphoma: A Challenging Diagnosis. 61
31123618 2018
50
[Clinicopathologic features of breast lymphoma in core needle biopsy]. 61
30317726 2018

Variations for Lymphosarcoma

Expression for Lymphosarcoma

Search GEO for disease gene expression data for Lymphosarcoma.

Pathways for Lymphosarcoma

Pathways related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.99 PTPRC IGH CD22 BCL6
2 11.66 SMARCA4 NR3C1 DNMT3A DNMT1
3 11.62 SMARCA4 BCL6 BCL2
4 10.51 GSR G6PD
5 10.27 SMARCA4 DNMT3A DNMT1 BCL2

GO Terms for Lymphosarcoma

Cellular components related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 DNMT1 BCL6

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.92 SMARCA4 NR3C1 DNMT3A DNMT1 BCL6
2 chromatin organization GO:0006325 9.76 SMARCA4 NR3C1 DNMT3A DNMT1
3 regulation of gene expression GO:0010468 9.73 PTPRC DNMT3A DNMT1 BCL2
4 negative regulation of cell growth GO:0030308 9.65 SMARCA4 BCL6 BCL2
5 response to gamma radiation GO:0010332 9.54 PTPRC BCL2
6 B cell differentiation GO:0030183 9.54 PTPRC BCL6 BCL2
7 DNA methylation GO:0006306 9.51 DNMT3A DNMT1
8 negative regulation of reactive oxygen species metabolic process GO:2000378 9.49 G6PD BCL2
9 pentose-phosphate shunt GO:0006098 9.4 H6PD G6PD
10 DNA methylation involved in embryo development GO:0043045 9.32 DNMT3A DNMT1
11 C-5 methylation of cytosine GO:0090116 9.26 DNMT3A DNMT1
12 pentose-phosphate shunt, oxidative branch GO:0009051 9.16 H6PD G6PD
13 positive regulation of B cell proliferation GO:0030890 9.13 PTPRC BCL6 BCL2
14 DNA methylation on cytosine GO:0032776 8.62 DNMT3A DNMT1

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.33 H6PD GSR G6PD
2 oxidoreductase activity, acting on CH-OH group of donors GO:0016614 9.32 H6PD G6PD
3 DNA-methyltransferase activity GO:0009008 9.26 DNMT3A DNMT1
4 DNA (cytosine-5-)-methyltransferase activity GO:0003886 8.96 DNMT3A DNMT1
5 glucose-6-phosphate dehydrogenase activity GO:0004345 8.62 H6PD G6PD

Sources for Lymphosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....